Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
pexacerfont · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| A1 | EXPERIMENTAL | - |
| A2 | ACTIVE_COMPARATOR | - |
| A3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| pexacerfont | DRUG | Tablets \& Capsules, Oral, 300mg loading dose then 100 mg, once daily, 1 week loading dose then 8 weeks |
| escitalopram | DRUG | Tablets \& Capsules, Oral, 10-20mg, once daily, 1 week loading dose then 8 weeks |
| placebo | DRUG | Tablets \& Capsules, Oral, 0 mg, once daily, 1 week loading dose then 8 weeks |
Inclusion Criteria: * Outpatient women ages 18-65 meeting Diagnostic and Statistical Manual of Mental Disorders Manual, Fourth Edition, Text Revision (DSM-IV TR) criteria for Generalized Anxiety Disorder (GAD), either moderate or severe (300.02) Exclusion Criteria: * Males * Patients who report a...
Pexacerfont is an investigational small molecule being studied for the treatment of Major Depressive Disorder and Generalized Anxiety Disorder. It is being developed by Bristol-Myers Squibb Company (BMY). As of now, it is in clinical development and has not been approved by the FDA.
The specific molecular target of Pexacerfont is not disclosed in available information. It is being studied for its potential effects in psychiatric conditions such as Major Depressive Disorder and Generalized Anxiety Disorder, but its mechanism of action has not been publicly detailed.
Pexacerfont is being developed by Bristol-Myers Squibb Company, a pharmaceutical company listed on the stock exchange under the ticker symbol BMY. The company has conducted clinical trials to evaluate the drug's safety and efficacy in psychiatric indications.
Pexacerfont has completed a Phase 1 trial for Major Depressive Disorder and a Phase 2 trial for Generalized Anxiety Disorder. Both trials are completed, and the drug is not yet approved. It remains an investigational compound in clinical development.
Pexacerfont has been studied in two completed clinical trials. NCT00135421 was a Phase 1 study in 271 female outpatients with Major Depressive Disorder in the United States. NCT00481325 was a Phase 2 study in 260 female outpatients with Generalized Anxiety Disorder, also in the United States.
Yes, Pexacerfont is also known as BMS-562086. The clinical trial NCT00135421 refers to the drug as BMS-562086 in its title, confirming that these names refer to the same investigational compound.